Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1990 1
1992 1
1993 1
1994 1
1995 1
1996 1
1999 1
2001 1
2004 2
2005 3
2006 2
2007 2
2008 6
2009 2
2010 4
2011 9
2012 4
2013 3
2014 3
2015 4
2016 6
2017 2
2018 8
2019 4
2020 12
2021 8
2022 8
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Results by year

Filters applied: . Clear all
Page 1
Discovering dominant tumor immune archetypes in a pan-cancer census.
Combes AJ, Samad B, Tsui J, Chew NW, Yan P, Reeder GC, Kushnoor D, Shen A, Davidson B, Barczak AJ, Adkisson M, Edwards A, Naser M, Barry KC, Courau T, Hammoudi T, Argüello RJ, Rao AA, Olshen AB; Immunoprofiler Consortium; Cai C, Zhan J, Davis KC, Kelley RK, Chapman JS, Atreya CE, Patel A, Daud AI, Ha P, Diaz AA, Kratz JR, Collisson EA, Fragiadakis GK, Erle DJ, Boissonnas A, Asthana S, Chan V, Krummel MF. Combes AJ, et al. Among authors: daud ai. Cell. 2022 Jan 6;185(1):184-203.e19. doi: 10.1016/j.cell.2021.12.004. Epub 2021 Dec 27. Cell. 2022. PMID: 34963056 Free PMC article.
TCR-sequencing in cancer and autoimmunity: barcodes and beyond.
Pauken KE, Lagattuta KA, Lu BY, Lucca LE, Daud AI, Hafler DA, Kluger HM, Raychaudhuri S, Sharpe AH. Pauken KE, et al. Among authors: daud ai. Trends Immunol. 2022 Mar;43(3):180-194. doi: 10.1016/j.it.2022.01.002. Epub 2022 Jan 25. Trends Immunol. 2022. PMID: 35090787 Free PMC article. Review.
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.
Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, Freeman GJ, Warren SE, Ong S, Browning E, Twitty CG, Pierce RH, Le MH, Algazi AP, Daud AI, Pai SI, Zippelius A, Weissleder R, Pittet MJ. Garris CS, et al. Among authors: daud ai. Immunity. 2018 Dec 18;49(6):1148-1161.e7. doi: 10.1016/j.immuni.2018.09.024. Epub 2018 Dec 11. Immunity. 2018. PMID: 30552023 Free PMC article.
Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment.
Pauken KE, Shahid O, Lagattuta KA, Mahuron KM, Luber JM, Lowe MM, Huang L, Delaney C, Long JM, Fung ME, Newcomer K, Tsai KK, Chow M, Guinn S, Kuchroo JR, Burke KP, Schenkel JM, Rosenblum MD, Daud AI, Sharpe AH, Singer M. Pauken KE, et al. Among authors: daud ai. J Exp Med. 2021 Apr 5;218(4):e20200920. doi: 10.1084/jem.20200920. J Exp Med. 2021. PMID: 33651880 Free PMC article.
A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments.
Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, Nelson AE, Loo K, Kumar R, Rosenblum MD, Alvarado MD, Wolf DM, Bogunovic D, Bhardwaj N, Daud AI, Ha PK, Ryan WR, Pollack JL, Samad B, Asthana S, Chan V, Krummel MF. Barry KC, et al. Among authors: daud ai. Nat Med. 2018 Aug;24(8):1178-1191. doi: 10.1038/s41591-018-0085-8. Epub 2018 Jun 25. Nat Med. 2018. PMID: 29942093 Free PMC article.
Immunotherapy for melanoma.
Cuevas LM, Daud AI. Cuevas LM, et al. Among authors: daud ai. Semin Cutan Med Surg. 2018 Jun;37(2):127-131. doi: 10.12788/j.sder.2018.028. Semin Cutan Med Surg. 2018. PMID: 30040090 Review.
Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity.
Binnewies M, Mujal AM, Pollack JL, Combes AJ, Hardison EA, Barry KC, Tsui J, Ruhland MK, Kersten K, Abushawish MA, Spasic M, Giurintano JP, Chan V, Daud AI, Ha P, Ye CJ, Roberts EW, Krummel MF. Binnewies M, et al. Among authors: daud ai. Cell. 2019 Apr 18;177(3):556-571.e16. doi: 10.1016/j.cell.2019.02.005. Epub 2019 Apr 4. Cell. 2019. PMID: 30955881 Free PMC article.
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma.
Robert C, Carlino MS, McNeil C, Ribas A, Grob JJ, Schachter J, Nyakas M, Kee D, Petrella TM, Blaustein A, Lotem M, Arance A, Daud AI, Hamid O, Larkin J, Anderson J, Krepler C, Grebennik D, Long GV. Robert C, et al. Among authors: daud ai. J Clin Oncol. 2023 Aug 20;41(24):3998-4003. doi: 10.1200/JCO.22.01599. Epub 2023 Jun 22. J Clin Oncol. 2023. PMID: 37348035
The Liver-Immunity Nexus and Cancer Immunotherapy.
Lee JC, Green MD, Huppert LA, Chow C, Pierce RH, Daud AI. Lee JC, et al. Among authors: daud ai. Clin Cancer Res. 2022 Jan 1;28(1):5-12. doi: 10.1158/1078-0432.CCR-21-1193. Epub 2021 Jul 20. Clin Cancer Res. 2022. PMID: 34285059 Free PMC article. Review.
Melanocytic Neoplasms, Introduction.
Daud AI. Daud AI. Semin Cutan Med Surg. 2018 Jun;37(2):87. doi: 10.12788/j.sder.2018.028. Semin Cutan Med Surg. 2018. PMID: 30040084 No abstract available.
97 results